Recent years, however, have witnessed an increasing evaluation of CXCR4-directed imaging and therapy in particular for patients with hematological malignancies, thereby expanding this theranostic concept towards hemato-oncology [6]. This evidence concerns the gene CXCR4 and hematologic disorder.